ES2060947T3 - Un nuevo sistema de suministro de anticuerpos para modificadores de la respuesta biologica. - Google Patents

Un nuevo sistema de suministro de anticuerpos para modificadores de la respuesta biologica.

Info

Publication number
ES2060947T3
ES2060947T3 ES90304734T ES90304734T ES2060947T3 ES 2060947 T3 ES2060947 T3 ES 2060947T3 ES 90304734 T ES90304734 T ES 90304734T ES 90304734 T ES90304734 T ES 90304734T ES 2060947 T3 ES2060947 T3 ES 2060947T3
Authority
ES
Spain
Prior art keywords
biological response
response modifiers
supply system
new antibody
antibody supply
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90304734T
Other languages
English (en)
Inventor
Michael G Rosenblum
Clyde William Wellen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Development Foundation
Original Assignee
Research Development Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Development Foundation filed Critical Research Development Foundation
Application granted granted Critical
Publication of ES2060947T3 publication Critical patent/ES2060947T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)

Abstract

LA PRESENTE INVENCION MUESTRA UN NUEVO CONJUGADO DE ANTICUERPO CON UNAS MODIFICACIONES DE LA RESPUESTA BIOLOGICA; EL SISTEMA DISTRIBUIDOR REPARTE LOS MODIFICADORES DE RESPUESTA BIOLOGICA ENTRE LAS CELULAS Y TEJIDOS ANTICATODOS. LA INVENCION TAMBIEN PRESENTA UN METODO PARA TRATAR ENFERMEDADES POR LA ADMINISTRACION DE LOS MODIFICADORES CONJUGADOS DE RESPUESTA BOLOGICA ANTICUERPO. POR EJEMPLO, UN ANTICUERPO CONJUGADO A UNA LINFOQUINA O CITOQUINA COMO EL TNF.
ES90304734T 1989-05-05 1990-05-01 Un nuevo sistema de suministro de anticuerpos para modificadores de la respuesta biologica. Expired - Lifetime ES2060947T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34823789A 1989-05-05 1989-05-05

Publications (1)

Publication Number Publication Date
ES2060947T3 true ES2060947T3 (es) 1994-12-01

Family

ID=23367161

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90304734T Expired - Lifetime ES2060947T3 (es) 1989-05-05 1990-05-01 Un nuevo sistema de suministro de anticuerpos para modificadores de la respuesta biologica.

Country Status (18)

Country Link
EP (1) EP0396387B1 (es)
JP (1) JP3589459B2 (es)
KR (1) KR0181294B1 (es)
CN (1) CN1072505C (es)
AT (1) ATE98873T1 (es)
AU (1) AU645747B2 (es)
CA (1) CA2015060C (es)
DE (1) DE69005352T2 (es)
DK (1) DK0396387T3 (es)
ES (1) ES2060947T3 (es)
FI (1) FI100092B (es)
IE (1) IE63847B1 (es)
IL (1) IL94167A (es)
NO (1) NO301168B1 (es)
NZ (1) NZ233413A (es)
PT (1) PT93966B (es)
SA (1) SA90110099B1 (es)
ZA (1) ZA902949B (es)

Families Citing this family (204)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69019609T2 (de) * 1989-07-07 1995-11-30 Takeda Chemical Industries Ltd Proteine und deren Herstellung.
US5314995A (en) * 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
DE69102265T2 (de) * 1990-02-06 1994-10-13 Takeda Chemical Industries, Ltd., Osaka Immunkomplexe.
IE62496B1 (en) * 1990-04-19 1995-02-08 Res Dev Foundation Antibody conjugates for treatment of neoplastic disease
US5349053A (en) * 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
US5594107A (en) * 1990-08-22 1997-01-14 University Of Saskatchewan Chimeric protein comprising an RTX-family cytotoxin and interferon-2 or interferon
US5273889A (en) * 1990-08-22 1993-12-28 University Of Saskatchewan Gamma-iterferon-leukotoxin gene fusions and uses thereof
EP0547163B1 (en) * 1990-08-29 2002-02-06 Centre Hospitalier Regional De Nantes Protein polyligands joined to a stable protein core
WO1992008801A1 (en) * 1990-11-09 1992-05-29 Abbott Laboratories Bridging antibody fusion constructs
US5650150A (en) * 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
ATE218889T1 (de) * 1990-11-09 2002-06-15 Stephen D Gillies Cytokine immunokonjugate
JPH06508821A (ja) * 1991-03-07 1994-10-06 セラジュン　インク ウイルス病治療のための細胞表面受容体を標的とする分子の使用
JP3105629B2 (ja) * 1991-04-23 2000-11-06 サングスタット メディカル コーポレイション 特異的結合ペアのメンバーの細胞活性調節接合体
US5326559A (en) * 1991-05-16 1994-07-05 Miller D Douglas Treatment of accelerated atheosclerosis with interleukin-2 receptor targeted molecules
US5679777A (en) * 1991-11-08 1997-10-21 Somatogen, Inc. Hemoglobins as drug delivery agents
GB9324807D0 (en) * 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
ATE207366T1 (de) * 1993-12-24 2001-11-15 Merck Patent Gmbh Immunokonjugate
GB9415379D0 (en) * 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
PT706799E (pt) * 1994-09-16 2002-05-31 Merck Patent Gmbh Imunoconjugados ii
US7597886B2 (en) 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7820798B2 (en) 1994-11-07 2010-10-26 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US6482927B1 (en) * 1995-11-27 2002-11-19 Millennium Pharmaceuticals, Inc. Chimeric proteins comprising the extracellular domain of murine Ob receptor
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
ATE239041T1 (de) * 1996-02-09 2003-05-15 Basf Ag Humane antikörper welche an humanen tnfalpha binden
ES2221717T3 (es) 1997-12-08 2005-01-01 Emd Lexigen Research Center Corp. Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general.
ATE490980T1 (de) 1998-03-19 2010-12-15 Human Genome Sciences Der gemeinsamen gamma-kette ähnlicher zytokinrezeptor
WO2000050620A2 (en) 1999-02-26 2000-08-31 Human Genome Sciences, Inc. Human endokine alpha and methods of use
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
WO2001010912A1 (en) 1999-08-09 2001-02-15 Lexigen Pharmaceuticals Corp. Multiple cytokine-antibody complexes
CA2391080A1 (en) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
AU2002219944B2 (en) 2000-11-28 2008-02-21 Medimmune, Llc Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
EP1294949A4 (en) 2000-06-15 2004-08-25 Human Genome Sciences Inc HUMAN TUMORNESCROSE FACTOR DELTA AND EPSILON
AU2001268427B2 (en) 2000-06-16 2007-03-29 Glaxosmithkline Intellectual Property Limited Antibodies that immunospecifically bind to blys
WO2001097844A1 (en) * 2000-06-22 2001-12-27 Idec Pharmaceuticals Corporation Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
CZ2003214A3 (cs) 2000-06-29 2003-08-13 Merck Patent Gmbh Zesílení odpovědi mediovaných fúzním proteinem protilátka-cytokin kombinovanou léčbou pomocí činidel zvyšujících uptake imunocytokinu
WO2002064612A2 (en) 2001-02-09 2002-08-22 Human Genome Sciences, Inc. Human g-protein chemokine receptor (ccr5) hdgnr10
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
DK1366067T3 (da) 2001-03-07 2012-10-22 Merck Patent Gmbh Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
JP2004536579A (ja) 2001-04-13 2004-12-09 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド 血管内皮増殖因子２
BR0209177A (pt) 2001-05-03 2004-10-05 Merck Patent Gmbh Anticorpo especìfico a tumor recombinante e uso do mesmo
MXPA03010747A (es) 2001-05-25 2004-03-02 Human Genome Sciences Inc Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral.
CA2454048C (en) 2001-07-17 2011-05-03 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins
US6867189B2 (en) 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
EP1454138B1 (en) 2001-12-04 2012-01-18 Merck Patent GmbH Immunocytokines with modulated selectivity
EP2270049A3 (en) 2002-04-12 2011-03-09 Medimmune, Inc. Recombinant anti-interleukin-9-antibody
GB0209896D0 (en) 2002-04-30 2002-06-05 Molmed Spa Conjugate
AU2003274463B2 (en) 2002-06-10 2009-10-29 University Of Rochester Gene differentially expressed in breast and bladder cancer and encoded polypeptides
US7232888B2 (en) 2002-07-01 2007-06-19 Massachusetts Institute Of Technology Antibodies against tumor surface antigens
ATE471946T1 (de) 2002-12-17 2010-07-15 Merck Patent Gmbh Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
AU2004206250B8 (en) 2003-01-21 2009-09-17 Bristol-Myers Squibb Company Polynucleotide encoding a novel acyl coenzyme a, monoacylglycerol acyltransferase-3 (MGAT3), and uses thereof
PL1606409T3 (pl) 2003-03-19 2011-02-28 Biogen Ma Inc Białko wiążące receptor Nogo
CA2525929A1 (en) 2003-05-13 2004-11-25 Chiron Corporation Methods of modulating metastasis and skeletal related events resulting from metastases
MX361174B (es) 2003-12-23 2018-11-29 Genentech Inc Anticuerpos anti-il13 novedosos y sus usos.
KR101163424B1 (ko) 2003-12-30 2012-07-13 메르크 파텐트 게엠베하 Ｉｌ－７ 융합 단백질
EP1699821B1 (en) 2003-12-31 2012-06-20 Merck Patent GmbH Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
CA2552590A1 (en) 2004-01-05 2005-07-21 Emd Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
PT1776136E (pt) 2004-06-24 2012-12-05 Biogen Idec Inc Tratamento de estados que envolvem desmielinização
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
WO2006002895A2 (en) * 2004-06-30 2006-01-12 Novartis Ag Conjugates of antibody and duoarmycin derivatives as antitumor agents
EP1789070B1 (en) 2004-08-03 2012-10-24 Biogen Idec MA Inc. Taj in neuronal function
CN101072793B (zh) 2004-12-09 2012-06-20 默克专利有限公司 具有降低的免疫原性的il-7变体
WO2006078776A2 (en) 2005-01-19 2006-07-27 The Trustees Of The University Of Pennsylvania Inhibitors and methods of treatment of cardiovascular diseases, and methods for identifying inhibitors
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
SI1904104T1 (sl) 2005-07-08 2013-12-31 Biogen Idec Ma Inc. Protitelesa SP35 in njihova uporaba
EP1904652A2 (en) 2005-07-08 2008-04-02 Brystol-Myers Squibb Company Single nucleotide polymorphisms associated with dose-dependent edema and methods of use thereof
DK2500030T4 (en) 2005-11-04 2018-10-29 Genentech Inc Use of complement pathway inhibitors for the treatment of eye diseases
EP1959979A4 (en) 2005-11-04 2010-01-27 Biogen Idec Inc PROCESS FOR PROMOTING AXON GROWTH AND SURVIVAL OF DOPAMINERGIC NEURONS
US20100028358A1 (en) 2005-11-07 2010-02-04 Wolfram Ruf Compositions and Methods for Controlling Tissue Factor Signaling Specificity
US20090175872A1 (en) 2005-12-02 2009-07-09 Biogen Idec Ma Inc. Treatment of Conditions Involving Demyelination
EP2526968A3 (en) 2006-01-27 2013-05-22 Biogen Idec MA Inc. Nogo receptor antagonists
KR20090010194A (ko) 2006-04-13 2009-01-29 노바티스 백신즈 앤드 다이아그노스틱스, 인크. 암의 치료, 진단 또는 검출 방법
BRPI0712850A8 (pt) 2006-06-07 2018-05-02 Bioalliance Cv anticorpos que reconhecem um epitopo contendo carboidrato em cd-43 e cea expressados em células cancerígenas e métodos de uso dos mesmos
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
EP2484696B1 (en) 2006-08-28 2017-08-16 Kyowa Hakko Kirin Co., Ltd. Antagonistic hLIGHT-specific human monoclonal antibodies
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
EP2099827B1 (en) 2006-12-18 2018-11-21 Genentech, Inc. Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases
HUE033325T2 (en) 2007-01-05 2017-11-28 Univ Zuerich Anti-beta-amyloid binder antibodies and their use
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
GEP20125693B (en) 2007-01-09 2012-11-26 Biogen Idec Inc Sp35 antibodies and usage thereof
EA017403B1 (ru) 2007-02-02 2012-12-28 Байоджен Айдек Эмэй Инк. Использование семафорина 6а в качестве промотора миелинизации и дифференцировки олигодендроцитов
WO2008112988A2 (en) 2007-03-14 2008-09-18 Novartis Ag Apcdd1 inhibitors for treating, diagnosing or detecting cancer
EP3067368A1 (en) 2007-04-27 2016-09-14 Genentech, Inc. Potent, stable and non-immunosuppressive anti-cd4 antibodies
EP2195023B1 (en) 2007-08-29 2018-03-07 Sanofi Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
CA2705851C (en) 2007-11-21 2016-11-01 Oregon Health & Science University Anti-factor xi monoclonal antibodies and methods of use thereof
CN105732813A (zh) 2007-12-18 2016-07-06 生物联合公司 识别癌细胞上表达的cd-43和cea的含糖表位的抗体及其使用方法
NZ586544A (en) 2007-12-26 2012-07-27 Vaccinex Inc Anti-c35 antibody in combination with an ani-her2 antibody in cancer therapies and methods
US20110020368A1 (en) 2008-03-25 2011-01-27 Nancy Hynes Treating cancer by down-regulating frizzled-4 and/or frizzled-1
CN102065870B (zh) 2008-04-16 2014-11-19 比奥根艾迪克Ma公司 使用聚亚烷基二醇和过渡金属分离生物大分子的方法
EP2315779A2 (en) 2008-07-09 2011-05-04 Biogen Idec MA Inc. Compositions comprising antibodies to lingo or fragments thereof
WO2010027364A1 (en) 2008-09-07 2010-03-11 Glyconex Inc. Anti-extended type i glycosphingolipid antibody, derivatives thereof and use
JP2012507299A (ja) * 2008-10-31 2012-03-29 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｌｉｇｈｔ標的分子およびその使用
HRP20150831T1 (hr) 2008-12-19 2015-10-09 Biogen International Neuroscience Gmbh Humana anti-alfa- sinuklein auto-protutijela
CN102341411A (zh) 2008-12-31 2012-02-01 比奥根艾迪克Ma公司 抗-淋巴细胞毒素抗体
EP2405920A1 (en) 2009-03-06 2012-01-18 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Novel therapy for anxiety
WO2010111180A1 (en) 2009-03-24 2010-09-30 Teva Biopharmaceuticals Usa, Inc. Humanized antibodies against light and uses thereof
EP2241323A1 (en) 2009-04-14 2010-10-20 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Tenascin-W and brain cancers
AU2010238858A1 (en) 2009-04-22 2011-12-08 Merck Patent Gmbh Antibody fusion proteins with modified FcRn binding sites
EP2427212B1 (en) 2009-05-08 2017-08-23 Vaccinex, Inc. Anti-cd100 antibodies and methods for using the same
MX2012001882A (es) 2009-08-13 2012-04-11 Crucell Holland Bv Anticuerpos contra el virus sincitial respiratorio (rsv) humano y metodos de uso.
EP2292266A1 (en) 2009-08-27 2011-03-09 Novartis Forschungsstiftung, Zweigniederlassung Treating cancer by modulating copine III
WO2011035205A2 (en) 2009-09-18 2011-03-24 Calmune Corporation Antibodies against candida, collections thereof and methods of use
EP2480573A1 (en) 2009-09-22 2012-08-01 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Treating cancer by modulating mex-3
WO2011045352A2 (en) 2009-10-15 2011-04-21 Novartis Forschungsstiftung Spleen tyrosine kinase and brain cancers
US20120213801A1 (en) 2009-10-30 2012-08-23 Ekaterina Gresko Phosphorylated Twist1 and cancer
CA2780221A1 (en) 2009-11-04 2011-05-12 Fabrus Llc Methods for affinity maturation-based antibody optimization
US20130004519A1 (en) 2010-03-05 2013-01-03 Ruth Chiquet-Ehrismann Smoci, tenascin-c and brain cancers
EP2561076A1 (en) 2010-04-19 2013-02-27 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Modulating xrn1
US20130089538A1 (en) 2010-06-10 2013-04-11 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute forBiomedical Researh Treating cancer by modulating mammalian sterile 20-like kinase 3
EP2591000B1 (en) 2010-07-09 2017-05-17 Janssen Vaccines & Prevention B.V. Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
WO2012025636A1 (en) 2010-08-27 2012-03-01 University Of Zurich Method for target and drug validation in inflammatory and/or cardiovascular diseases
EP2611832B1 (en) 2010-09-02 2017-11-29 Vaccinex, Inc. Anti-cxcl13 antibodies and methods of using the same
US20130171159A1 (en) 2010-09-10 2013-07-04 Brian Arthur Hemmings Phosphorylated twist1 and metastasis
LT2627672T (lt) 2010-10-11 2018-12-10 Biogen International Neuroscience Gmbh Žmogaus antikūnai prieš tau baltymą
EP2640738A1 (en) 2010-11-15 2013-09-25 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Anti-fungal agents
CN103380145B (zh) 2010-12-17 2016-10-12 生物控股有限公司 人类抗-sod1抗体
WO2012125775A1 (en) 2011-03-16 2012-09-20 Sanofi Uses of a dual v region antibody-like protein
EP2717911A1 (en) 2011-06-06 2014-04-16 Novartis Forschungsstiftung, Zweigniederlassung Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer
US9244074B2 (en) 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
US9561274B2 (en) 2011-06-07 2017-02-07 University Of Hawaii Treatment and prevention of cancer with HMGB1 antagonists
PL2723379T3 (pl) 2011-06-23 2019-05-31 Biogen Int Neuroscience Gmbh Cząsteczki wiążące przeciwko alfa-synukleinie
US20140234903A1 (en) 2011-09-05 2014-08-21 Eth Zurich Biosynthetic gene cluster for the production of peptide/protein analogues
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
US20130108641A1 (en) 2011-09-14 2013-05-02 Sanofi Anti-gitr antibodies
ES2697674T3 (es) 2011-11-01 2019-01-25 Bionomics Inc Procedimientos para bloquear el crecimiento de células madre cancerosas
EP2773664A1 (en) 2011-11-01 2014-09-10 Bionomics, Inc. Anti-gpr49 antibodies
WO2013067060A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Anti-gpr49 antibodies
HK1201855A1 (en) 2011-11-01 2015-09-11 Bionomics, Inc. Antibodies and methods of treating cancer
WO2013068431A1 (en) 2011-11-08 2013-05-16 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research New treatment for neurodegenerative diseases
US20140294732A1 (en) 2011-11-08 2014-10-02 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute Early diagnostic of neurodegenerative diseases
CN107353342B (zh) 2011-12-05 2021-08-10 X 博迪生物科学公司 PDGF受体β结合多肽
WO2013102825A1 (en) 2012-01-02 2013-07-11 Novartis Ag Cdcp1 and breast cancer
US9890213B2 (en) 2012-03-02 2018-02-13 Vaccinex, Inc. Methods for the treatment of B cell-mediated inflammatory diseases
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
WO2013148296A1 (en) 2012-03-28 2013-10-03 Sanofi Antibodies to bradykinin b1 receptor ligands
US20150266961A1 (en) 2012-03-29 2015-09-24 Novartis Forschungsstiftung, Zweigniederlassung, Fridrich Miescher Institute Inhibition of interleukin-8 and/or its receptor cxcr1 in the treatment of her2/her3-overexpressing breast cancer
WO2013169657A1 (en) 2012-05-07 2013-11-14 Sanofi Methods for preventing biofilm formation
US9796780B2 (en) 2012-05-14 2017-10-24 Biogen Ma Inc. LINGO-2 antagonists for treatment of conditions involving motor neurons
WO2013175276A1 (en) 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
SG11201408330XA (en) 2012-05-24 2015-01-29 Mountgate Group Ltd Compositions and methods related to prevention and treatment of rabies infection
WO2014001482A1 (en) 2012-06-29 2014-01-03 Novartis Forschungsstiftung, Zweigniererlassung, Friedrich Miescher Institute For Biomedical Research Treating diseases by modulating a specific isoform of mkl1
US20150184154A1 (en) 2012-07-05 2015-07-02 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear New treatment for neurodegenerative diseases
US20150224190A1 (en) 2012-07-06 2015-08-13 Mohamed Bentires-Alj Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the IL-8/CXCR interaction
PL3489261T3 (pl) 2012-08-24 2021-08-16 The Regents Of The University Of California Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
JP6284548B2 (ja) 2012-12-21 2018-02-28 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． ヒト抗タウ抗体
EP3517545A1 (en) 2012-12-31 2019-07-31 Neurimmune Holding AG Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
CA2902442A1 (en) 2013-03-08 2014-09-12 Vaccinex, Inc. Anti-cxcl13 antibodies and associated epitope sequences
AU2014233198B2 (en) 2013-03-15 2019-06-27 Sutter West Bay Hospitals Falz for use as a target for therapies to treat cancer
EP3003390B1 (en) 2013-06-06 2021-07-07 Pierre Fabre Médicament Anti-c10orf54 antibodies and uses thereof
US20160178610A1 (en) 2013-08-07 2016-06-23 Friedrich Miescher Institute For Biomedical Research New screening method for the treatment Friedreich's ataxia
TW201722994A (zh) 2013-08-13 2017-07-01 賽諾菲公司 胞漿素原活化素抑制劑-１（ｐａｉ-１）之抗體及其用途
BR112016002753A2 (pt) 2013-08-13 2017-11-21 Sanofi Sa anticorpos contra o inibidor-1 de ativador de plasminogênio (pai-1) e usos dos mesmos
LT3060229T (lt) 2013-10-24 2021-09-27 Astrazeneca Ab Stabilios vandeninės antikūno vaistinės formos
EP3450571B1 (en) 2014-02-24 2023-04-05 Celgene Corporation Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
CA2943242A1 (en) 2014-03-21 2015-09-24 X-Body, Inc. Bi-specific antigen-binding polypeptides
CA2944649C (en) 2014-04-04 2022-06-21 Bionomics, Inc. Humanized antibodies that bind lgr5
EP3154579A1 (en) 2014-06-13 2017-04-19 Friedrich Miescher Institute for Biomedical Research New treatment against influenza virus
EP3157535A1 (en) 2014-06-23 2017-04-26 Friedrich Miescher Institute for Biomedical Research Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small rnas
US20170165261A1 (en) 2014-07-01 2017-06-15 Brian Arthur Hemmings Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
EP3174898A2 (en) 2014-07-29 2017-06-07 Neurimmune Holding AG Human-derived anti-huntingtin (htt) antibodies and uses thereof
WO2016046768A1 (en) 2014-09-24 2016-03-31 Friedrich Miescher Institute For Biomedical Research Lats and breast cancer
CA2960925A1 (en) 2014-09-30 2016-04-07 Neurimmune Holding Ag Human-derived anti-dipeptide repeats (dprs) antibody
BR112017008383A2 (en) 2014-10-31 2018-07-31 Medimmune, Llc improved production method
KR102693806B1 (ko) 2014-12-11 2024-08-09 피에르 파브르 메디카먼트 항-c10orf54 항체들 및 그들의 용도들
WO2016112270A1 (en) 2015-01-08 2016-07-14 Biogen Ma Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders
PL3265123T3 (pl) 2015-03-03 2023-03-13 Kymab Limited Przeciwciała, zastosowania i sposoby
MX387295B (es) 2015-03-31 2025-03-18 Medimmune Ltd Nueva forma de interleucina-33 (il33), formas mutadas de interleucina-33 (il33), anticuerpos, ensayos y métodos para usar los mismos.
EP3349791A1 (en) 2015-09-15 2018-07-25 Board of Regents, The University of Texas System T-cell receptor (tcr)-binding antibodies and uses thereof
US20180348224A1 (en) 2015-10-28 2018-12-06 Friedrich Miescher Institute For Biomedical Resear Ch Tenascin-w and biliary tract cancers
WO2017120534A1 (en) 2016-01-08 2017-07-13 Bioalliance C.V. Tetravalent anti-psgl-1 antibodies and uses thereof
JP6979976B2 (ja) 2016-03-10 2021-12-15 ヴィエラ バイオ，インコーポレーテッド Ｉｌｔ７結合分子及びその使用方法
US10745487B2 (en) 2016-03-22 2020-08-18 Bionomics Limited Method of treating cancer by administering an anti-LGR5 monoclonal antibody
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
JP7246320B2 (ja) 2017-05-05 2023-03-27 バクシネックス インコーポレーティッド ヒト抗セマフォリン４ｄ抗体
CN111587123A (zh) 2017-11-09 2020-08-25 品通治疗有限公司 用于生成和使用人源化构象特异性磷酸化的τ抗体的方法和组合物
CN111727075B (zh) 2017-11-27 2024-04-05 普渡制药公司 靶向人组织因子的人源化抗体
KR20200131846A (ko) 2018-03-14 2020-11-24 메모리얼 슬로안 케터링 캔서 센터 항-폴리시알산 항체 및 그 용도
TW202016144A (zh) 2018-06-21 2020-05-01 日商第一三共股份有限公司 包括cd3抗原結合片段之組成物及其用途
MX2021009662A (es) 2019-02-13 2021-09-08 Brigham & Womens Hospital Inc Anticuerpos anti-adresina de ganglios linfaticos perifericos y usos de los mismos.
CA3133074A1 (en) 2019-03-11 2020-09-17 Memorial Sloan Kettering Cancer Center Cd22 antibodies and methods of using the same
JP7575401B2 (ja) 2019-04-03 2024-10-29 ジェンザイム・コーポレーション 断片化が低減した抗アルファベータｔｃｒ結合ポリペプチド
TWI883004B (zh) 2019-05-24 2025-05-11 法商賽諾菲公司 治療全身性硬化症之方法
CN114929743B (zh) 2019-09-05 2026-01-02 纪念斯隆凯特琳癌症中心 抗steap1抗体及其用途
US20230220085A1 (en) 2020-02-28 2023-07-13 The Brigham And Women’S Hospital, Inc. Selective modulation of transforming growth factor beta superfamily signaling via multi-specific antibodies
WO2021202463A1 (en) 2020-03-30 2021-10-07 Danisco Us Inc Anti-rsv antibodies
WO2021203013A2 (en) 2020-04-03 2021-10-07 Viela Bio, Inc. Methods of treating immune mediated pulmonary injury
US20230382978A1 (en) 2020-10-15 2023-11-30 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
WO2022087274A1 (en) 2020-10-21 2022-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies that neutralize type-i interferon (ifn) activity
EP4277665A1 (en) 2021-01-13 2023-11-22 Memorial Sloan Kettering Cancer Center Anti-dll3 antibody-drug conjugate
CN117425501A (zh) 2021-01-13 2024-01-19 纪念斯隆凯特琳癌症中心 抗体-吡咯并苯二氮䓬衍生物缀合物
EP4294834A2 (en) 2021-02-19 2023-12-27 The United States of America, as represented by The Secretary, Department of Health and Human Services Single domain antibodies that neutralize sars-cov-2
JP2024540484A (ja) 2021-11-17 2024-10-31 アルトゥルバイオ， インコーポレイテッド 抗ｐｓｇｌ－１抗体をｊａｋ阻害剤と組み合わせて使用してｔ細胞媒介性炎症性疾患またはがんを治療する方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1564666A (en) * 1978-05-31 1980-04-10 Ng Mun Hon Heterocomplexes of interferon with immunoglobulin and pharmaceutical compositions thereof
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
US4703004A (en) * 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4590071A (en) * 1984-09-25 1986-05-20 Xoma Corporation Human melanoma specific immunotoxins
DE3585778D1 (de) * 1984-12-05 1992-05-07 Salk Inst For Biological Studi Monoklonaler antikoerper, spezifisch fuer brustkrebszelloberflaechenantigen.
NO881077L (no) * 1987-03-11 1988-09-12 Univ Michigan Kjemo-radio-immuno-konjugater.
WO1988009343A1 (fr) * 1987-05-29 1988-12-01 Sagami Chemical Research Center Proteine fusionnee contenant une lymphotoxine
PH26813A (en) * 1987-09-02 1992-11-05 Ciba Geigy Ag Conjugates of cytokines with immunoglobulins
CA1329119C (en) * 1988-03-29 1994-05-03 Milton David Goldenberg Cytotoxic therapy
IE62463B1 (en) * 1988-07-07 1995-02-08 Res Dev Foundation Immunoconjugates for cancer diagnosis and therapy

Also Published As

Publication number Publication date
NZ233413A (en) 1992-05-26
IE901405L (en) 1990-11-05
IL94167A0 (en) 1991-01-31
ZA902949B (en) 1992-02-26
AU5379590A (en) 1990-11-08
ATE98873T1 (de) 1994-01-15
PT93966B (pt) 1996-12-31
EP0396387A3 (en) 1991-04-03
NO901986L (no) 1990-11-06
PT93966A (pt) 1991-02-08
IL94167A (en) 1997-02-18
JPH02306923A (ja) 1990-12-20
EP0396387A2 (en) 1990-11-07
CA2015060C (en) 2008-03-18
HK1006678A1 (en) 1999-03-12
FI100092B (fi) 1997-09-30
KR0181294B1 (ko) 1999-03-20
FI902245A0 (fi) 1990-05-04
DE69005352T2 (de) 1994-04-14
EP0396387B1 (en) 1993-12-22
IE63847B1 (en) 1995-06-14
JP3589459B2 (ja) 2004-11-17
CN1072505C (zh) 2001-10-10
DK0396387T3 (da) 1994-02-14
SA90110099B1 (ar) 2004-02-15
AU645747B2 (en) 1994-01-27
DE69005352D1 (de) 1994-02-03
CA2015060A1 (en) 1990-11-05
NO301168B1 (no) 1997-09-22
NO901986D0 (no) 1990-05-04
CN1047035A (zh) 1990-11-21
KR900017612A (ko) 1990-12-19

Similar Documents

Publication Publication Date Title
PT93966A (pt) Novo sistema de libertacao de anticorpos para modificadores de resposta biologica
ES2135458T3 (es) Sistema de medicamento que comprende una matriz de gel que contiene un farmaco inmobilizado.
ES2132105T3 (es) 2-aminometil-cromanos como principios activos en farmacos para el tratamiento de enfermedades del sistema nervioso central.
ES2057124T3 (es) Producto terapeutico para el tratamiento de estados peri- o post-menopausicos.
ATE235230T1 (de) Aufnahme von biologisch aktiven molekülen in bioaktives glas
ES2053719T3 (es) Dimetilvermectinas no naturales y procedimiento para su preparacion.
ES2118251T3 (es) Preparaciones de microparticulas a base de copolimeros biologicamente degradables.
MX9301348A (es) Nuevos compuestos que tienen actividad farmacologica, proceso para su preparacion y composicion farmaceutica que los comprende.
ES2038718T3 (es) Sistema terapeutico transdermal para la aplicacion de productos activos sobre la piel.
PT781778E (pt) Novos pro-farmacos de paclitaxel metodo para a sua preparacao bem como a sua utilizacao em quimioterapia selectiva
MX9306220A (es) Ptp 1d: una proteina tirosina fosfatasa novedosa.
ES2061528T3 (es) Un procedimiento para preparar nuevos derivados de poliamina.
ATE113470T1 (de) Gehirnspezifische zubereitung mit gesteuerter abgabe.
FI870808L (fi) 9-alfa, 11-beta-substituerade och 11-beta-substituerade estraner.
ES2145360T3 (es) Sales cristalinas y estables de acido tetrahidrofolico.
CO4940430A1 (es) Compuestos policiclicos que contienen estaurosporina hidrogenada con propiedades farmacologicas convenientes y un efecto inhibidor sobre el crecimiento de las celulas tumorales
ES2064613T3 (es) Produccion de agentes citotoxicos.
ES2095984T3 (es) 2,3-dihidropirano(2,3-b)piridinas aminometil sustituidas, procedimiento para su preparacion y su uso en medicamentos.
ES2063004T3 (es) Antibioticos ab-006 y procedimiento para su produccion.
ES2130506T3 (es) Uso de 5-acil-1,4-dihidropiridinas para tratamiento de enfermedades del snc.
MX9301608A (es) Acidos 7-oxo-7h-pirido(1,2,3,de)(1,4)benzoxacin-6-carboxilico y sus esteres, procedimiento para su preparacion y medicamentos que los contienen.
ES2144857T3 (es) Utilizacion de derivados benzonaftalenicos para la fabricacion de medicamentos destinados para el tratamiento de las enfermedades del sistema nervioso.
ES2121627T3 (es) Sales medicamentosas.
MX9505097A (es) 1,4-dihidropiridinas con estructura puente en la posicion 1,2, procedimiento para su obtencion y medicamentos que las contienen.
ES2103412T3 (es) Dihidropiridinas sustituidas con 4-heterociclilo.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 396387

Country of ref document: ES